{"id":"open-label-fondaparinux","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Bleeding (major and minor)"},{"rate":"0.1-1","effect":"Thrombocytopenia"},{"rate":"2-5","effect":"Injection site reactions"},{"rate":"1-2","effect":"Anemia"},{"rate":"1-2","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201202","moleculeType":"Oligosaccharide","molecularWeight":"1508.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fondaparinux is a synthetic pentasaccharide that binds to antithrombin III and potentiates its inhibition of Factor Xa. By blocking Factor Xa activity, it interrupts the intrinsic and common pathways of the coagulation cascade, reducing thrombin generation and preventing thrombosis without directly inhibiting thrombin itself.","oneSentence":"Fondaparinux selectively inhibits Factor Xa, a key enzyme in the coagulation cascade, thereby preventing thrombin generation and blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:26.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute deep vein thrombosis (DVT)"},{"name":"Acute pulmonary embolism (PE)"},{"name":"Prophylaxis of venous thromboembolism in patients undergoing hip fracture surgery, hip replacement surgery, or knee replacement surgery"},{"name":"Acute coronary syndrome (unstable angina and non-ST-segment elevation myocardial infarction)"}]},"trialDetails":[{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT06370273","phase":"PHASE3","title":"Thromboprophylaxis in Lower Limb Immobilisation","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-11-12","conditions":"Thrombosis, Injury Leg","enrollment":10044},{"nctId":"NCT02798471","phase":"PHASE3","title":"Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-03-27","conditions":"Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)","enrollment":290},{"nctId":"NCT01895777","phase":"PHASE3","title":"Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-09-25","conditions":"Venous Thromboembolism","enrollment":267},{"nctId":"NCT02234843","phase":"PHASE3","title":"EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-11-13","conditions":"Venous Thromboembolism","enrollment":500},{"nctId":"NCT01857583","phase":"PHASE3","title":"Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2012-03","conditions":"Venous Thromboembolism","enrollment":80},{"nctId":"NCT00381888","phase":"PHASE2","title":"Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2007-01","conditions":"Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer","enrollment":44},{"nctId":"NCT00790907","phase":"PHASE4","title":"Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Acute Coronary Syndrome","enrollment":3235},{"nctId":"NCT00843492","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Thrombosis, Venous","enrollment":1351},{"nctId":"NCT00555438","phase":"PHASE4","title":"Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2007-06","conditions":"Major Orthopaedic Surgery and Renal Impairment","enrollment":451}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Open label fondaparinux","genericName":"Open label fondaparinux","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fondaparinux selectively inhibits Factor Xa, a key enzyme in the coagulation cascade, thereby preventing thrombin generation and blood clot formation. Used for Acute deep vein thrombosis (DVT) treatment, Acute pulmonary embolism (PE) treatment, Prophylaxis of venous thromboembolism in patients undergoing hip fracture surgery, hip replacement surgery, or knee replacement surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}